Everence Capital Management’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-4,340
Closed -$491K 856
2025
Q1
$491K Hold
4,340
0.03% 375
2024
Q4
$458K Sell
4,340
-1,560
-26% -$167K 0.03% 396
2024
Q3
$637K Hold
5,900
0.04% 348
2024
Q2
$710 Hold
5,900
0.05% 294
2024
Q1
$779 Hold
5,900
0.05% 279
2023
Q4
$718K Hold
5,900
0.05% 293
2023
Q3
$662 Hold
5,900
0.05% 306
2023
Q2
$751K Hold
5,900
0.06% 261
2023
Q1
$762 Hold
5,900
0.06% 271
2022
Q4
$752 Buy
+5,900
New +$685K 0.06% 260
2016
Q4
Sell
-6,118
Closed -$772K 346
2016
Q3
$772K Hold
6,118
0.23% 128
2016
Q2
$715K Hold
6,118
0.22% 132
2016
Q1
$633K Hold
6,118
0.2% 151
2015
Q4
$609K Hold
6,118
0.2% 150
2015
Q3
$558K Hold
6,118
0.19% 153
2015
Q2
$649K Buy
6,118
+1,582
+35% +$175K 0.21% 149
2015
Q1
$530K Hold
4,536
0.18% 173
2014
Q4
$500K Buy
4,536
+1,563
+53% +$165K 0.17% 173
2014
Q3
$287K Hold
2,973
0.1% 220
2014
Q2
$300K Hold
2,973
0.11% 220
2014
Q1
$273K Hold
2,973
0.11% 226
2013
Q4
$269K Hold
2,973
0.11% 226
2013
Q3
$237K Hold
2,973
0.1% 231
2013
Q2
$216K Buy
+2,973
New +$222K 0.1% 235

Other funds holding ZBH

Everence Capital Management's ZBH Position: Q2 2025 in Review

Everence Capital Management sold out of Zimmer Biomet (ZBH) in Q2 2025, closing a stake of 4,340 shares — an estimated $491K sold.

Everence Capital Management first reported a position in ZBH in Q2 2013 and held it in 24 quarters. The position peaked at $772K in Q3 2016. 934 funds tracked by Wall St. Rank hold ZBH as of Q2 2025.

  • Everence Capital Management reported no remaining Zimmer Biomet position as of Q2 2025 after selling out during the quarter.
  • Everence Capital Management sold 4,340 Zimmer Biomet shares in Q2 2025, an estimated $491K.
  • Everence Capital Management first reported a position in Zimmer Biomet in Q2 2013 and held it in 24 quarters.
  • Everence Capital Management's Zimmer Biomet position peaked at $772K in Q3 2016.
  • 934 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2025.

Based on Everence Capital Management's 13F filing for Q2 2025, filed 29 Jul 2025.